Table of contents

• Overview of the trial
• Who was studied
• Treatment groups and study design
• What the trial measured
• Phase and status
• What these results mean for patients

Overview of the trial

The provided clinical trial studied Human Hepatitis B Immunoglobulin in people with chronic hepatitis B.^[1] The trial title was “Effective treatment of Hepatitis B with specific immune antibodies,” and it was designed to test whether a 12-week treatment period could improve a key hepatitis B marker.^[1]

Who was studied

The trial included people with chronic hepatitis B, which is a long-lasting hepatitis B infection.^[1] The enrollment was small, with 20 participants in total.^[1] This means the study was focused on a limited group rather than a large population.

Treatment groups and study design

This was an interventional study, which means researchers assigned treatment and then observed the results.^[1] The interventions listed were Hepatect CP 50 I.E./ml infusion solution and Zutectra 500 IU solution for injection in a pre-filled syringe.^[1] These were given in two different cohorts, meaning two groups of patients were followed in the study.^[1]

The trial brief summary says the researchers wanted to evaluate the efficacy of 12 weeks of treatment with hepatitis B immunoglobulins in these two cohorts.^[1] In simple terms, they wanted to see whether the treatment helped patients reach the study goal.

What the trial measured

The primary outcome was HBsAg negativity at week 12 of antiviral therapy.^[1] HBsAg is a blood marker used in hepatitis B, and “negativity” means it was not detected in the test.^[1] This outcome was used to judge whether the treatment had a meaningful effect after 12 weeks.

Because the trial report provided only one main outcome, the study appears to have focused on a clear and direct measure of response rather than many different endpoints.^[1] An endpoint is the main result a trial uses to judge success.

Phase and status

The study was a Phase 2 trial.^[1] Phase 2 studies usually look at whether a treatment may work in a specific group of patients, after earlier testing has already taken place.

The trial status was Completed.^[1] This means the study ended as planned and the data collection was finished.

What these results mean for patients

For patients, this trial shows that Human Hepatitis B Immunoglobulin was being studied as part of a research effort in chronic hepatitis B, not as a general treatment description.^[1] The main question was whether treatment could help patients become HBsAg negative after 12 weeks.^[1] Because the study was small and focused, it gives early clinical information about treatment response in a defined group.

Only one trial was provided in the source data, so the article reflects that single study and its main features.^[1]